(ABVX) Abivax - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: PA (France) | Market Cap: 8.159m EUR | Total Return: 1928.7% in 12m
Avg Turnover: 11.5M
Warnings
Interest Coverage Ratio -10.2 is critical
Altman Z'' -11.06 < 1.0 - financial distress zone
Volatile
Tailwinds
Leader
Abivax SA is a Paris-based, clinical-stage biotechnology company focused on modulating the immune system to treat chronic inflammatory diseases. The firm’s primary therapeutic approach involves stabilizing immune responses through its lead drug candidate, obefazimod.
The company is currently advancing obefazimod through Phase 3 clinical trials for ulcerative colitis and Phase 2b trials for Crohn’s disease. In the biotechnology sector, clinical-stage companies typically operate without recurring revenue, funding intensive R&D cycles through equity raises or strategic partnerships until regulatory approval is achieved.
The global market for inflammatory bowel disease (IBD) treatments is characterized by high barriers to entry due to stringent regulatory requirements and the necessity for long-term safety data. For a deeper analysis of these clinical milestones, consult the data on ValueRay.
- Obefazimod Phase 3 clinical trial results for ulcerative colitis determine core valuation
- Expansion into Crohn’s Disease Phase 2b trials broadens total addressable market
- FDA and EMA regulatory approval timelines dictate long-term commercialization prospects
- Cash runway and future capital raises impact share price through dilution
- Competition from established JAK inhibitors and biologics pressures future market share
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.46 > 0.02 and ΔFCF/TA 64.76 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.41 > 3% & CFO -242.5m > Net Income -541.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.5m) vs 12m ago 10.09% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 5.26%; Δ -5.26% > 0%) |
| Interest Coverage Ratio: -10.16 > 6 (EBITDA TTM -377.5m / Interest Expense TTM 37.3m) |
| A: 0.84 (Total Current Assets 551.2m - Total Current Liabilities 63.0m) / Total Assets 584.3m |
| B: -1.26 (Retained Earnings -738.5m / Total Assets 584.3m) |
| C: -0.96 (EBIT TTM -378.5m / Avg Total Assets 394.8m) |
| D: -5.69 (Book Value of Equity -735.4m / Total Liabilities 129.1m) |
| Altman-Z'' = -11.06 = D |
As of May 24, 2026, the stock is trading at EUR 105.90 with a total of 206,613 shares traded.
Over the past week, the price has changed by +6.92%,
over one month by +6.81%,
over three months by -3.90% and
over the past year by +1928.74%.
Abivax has no consensus analysts rating.
P/E Forward = 1.0044
P/S = 1684.7207
P/B = 18.3768
Revenue TTM = 0.0 EUR
EBIT TTM = -378.5m EUR
EBITDA TTM = -377.5m EUR
Long Term Debt = 15.9m EUR (from longTermDebt, two quarters ago)
Short Term Debt = 1.30m EUR (from shortTermDebt, last quarter)
Debt = 33.9m EUR (from shortLongTermDebtTotal, last quarter) + Leases 1.86m
Net Debt = -496.4m EUR (calculated: Debt 33.9m - CCE 530.4m)
Enterprise Value = 7.66b EUR (8.16b + Debt 33.9m - CCE 530.4m)
Interest Coverage Ratio = -10.16 (Ebit TTM -378.5m / Interest Expense TTM 37.3m)
EV/FCF = -28.72x (Enterprise Value 7.66b / FCF TTM -266.8m)
FCF Yield = -3.48% (FCF TTM -266.8m / Enterprise Value 7.66b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.07m) / Revenue TTM)
Tobins Q-Ratio = 13.11 (Enterprise Value 7.66b / Total Assets 584.3m)
Interest Expense / Debt = 109.7% (Interest Expense 37.3m / Debt 33.9m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -283.9m (EBIT -378.5m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 8.75 (Total Current Assets 551.2m / Total Current Liabilities 63.0m)
Debt / Equity = 0.07 (Debt 33.9m / totalStockholderEquity, last quarter 455.2m)
Debt / EBITDA = 1.32 (negative EBITDA) (Net Debt -496.4m / EBITDA -377.5m)
Debt / FCF = 1.86 (negative FCF - burning cash) (Net Debt -496.4m / FCF TTM -266.8m)
Total Stockholder Equity = 227.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -137.2% (out of range, set to none)
RoE = -56.07% (Net Income TTM -541.8m / Total Stockholder Equity 966.4m)
RoCE = -38.54% (EBIT -378.5m / Capital Employed (Equity 966.4m + L.T.Debt 15.9m))
RoIC = -54.32% (negative operating profit) (NOPAT -283.9m / Invested Capital 522.6m)
WACC = 16.63% (E(8.16b)/V(8.19b) * Re(16.70%) + (debt cost/tax rate unavailable))
Discount Rate = 16.70% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 91.11 | Cagr: 3.47k%
[DCF] Fair Price = unknown (Cash Flow -266.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -3.37 | # QB: -2
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -1.83 | # QB: -1
EPS current Quarter (2026-06-30): EPS=-0.89 | Chg30d=N/A | Revisions=N/A | Analysts=2
EPS current Year (2026-12-31): EPS=-3.52 | Chg30d=-17.60% | Revisions=-25% | GrowthEPS=+27.2% | GrowthRev=-34.1%
EPS next Year (2027-12-31): EPS=-3.12 | Chg30d=-1.24% | Revisions=-14% | GrowthEPS=+11.2% | GrowthRev=+3789.2%
[Analyst] Revisions Ratio: -25%